Chronic myelomonocytic leukaemia program in Pharmaceutical Benefits Scheme (PBS) 012-22062453
Expand allThis document outlines details of PBS-subsidised azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).
Chronic myelomonocytic leukaemia and listing dates
Chronic myelomonocytic leukaemia is a chronic blood cancer in which a person’s bone marrow creates too many monocytes, a type of white blood cell.
Listing dates are:
- azacitidine - 1 February 2011, and
- decitabine+cedazuridine - 1 October 2022
See Written Authority Required Drugs for more details.
Enquiries
- Transfer enquiries about prescription arrangements for azacitidine to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated
- Transfer enquiries about prescription arrangements for decitabine+cedazuridine to PBS authority approvals
The Resources page contains:
- application forms
- contact details
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing Complex Authority Required Listings
Written Authority Required Drugs